3,0
7 dec 2023
Voormalige werknemer, meer dan 5 jaar
Minneapolis, MN
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht
Pluspunten
Good benefits, good people, robust portfolio of science, ok work/life balance
Minpunten
Upper management continues to make decisions that hamstring the science (ex. letting CRISPR license expire while developing gene editing technology, wants to expand into C> but lays off C> team), layoffs two years in a row in December, <50% trust in upper management in company survey, shareholders rejected the outrageous executive compensation plan so hard it ended up in the Star Tribune (Nov 1 2023)